| abstract |
(57) [Summary]nDisclosed are monoclonal antibodies that specifically bind to human CD23 (FceRII / CD23), a low-affinity receptor for IgE, and that contain either human γ1 or human γ3 constant domains. The antibodies are useful for modulating or suppressing inducible IgE expression. Thus, they have utility in treating or preventing disease states where suppression of inducible IgE production is therapeutically desirable, such as allergic conditions, autoimmune diseases and inflammatory diseases. |